Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 11/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.46 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.44 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6454291 | 0.85 | HTT (0.42) | SYKHTTSGMS2 | |
| SCHEMBL6448824 | 0.81 | GRIN1 (0.46) | SYKAURKBINCENPSLC16A3SLC16A1 | |
| SCHEMBL6528085 | 0.81 | SYK (0.48) | SYKAURKBINCENPSLC16A3ABCB1 | |
| SCHEMBL6449630 | 0.78 | SYK (0.54) | SYKAURKBINCENPSLC16A3SLC16A1 | |
| SCHEMBL6451994 | 0.73 | PTGER1 (0.42) | SYKABCB1HTR1ADRD2TSHR | |
| SCHEMBL6530306 | 0.69 | SYK (0.47) | SYKAURKBINCENPKDM4EALDH1A1 | |
| SCHEMBL1094535 | 0.69 | SCN9A (0.47) | AURKBINCENPPTGER1 | |
| SCHEMBL19089278 | 0.68 | SYK (0.67) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL6448897 | 0.67 | MAOB (0.48) | SYKABCB1HTR1ADRD2MAOB | |
| SCHEMBL13791570 | 0.67 | MAOB (0.62) | ABCB1HTR1ADRD2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | SYK 4094/4885AURKB 1462/4885INCENP 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.